Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 29;20(10):56.
doi: 10.1007/s11934-019-0932-2.

Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma

Vidhya Karivedu  1 , Amit L Jain  2 , Thomas J Eluvathingal  3 , Abhinav Sidana  4   5
Affiliations
Review

Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma

Vidhya Karivedu et al. Curr Urol Rep. .

Abstract

Purpose of review: The clinical role of fluorine-18 fluoro-2-deoxyglucose (FDG)-positron emission tomography (PET) in renal cell carcinoma (RCC) is still evolving. Use of FDG PET in RCC is currently not a standard investigation in the diagnosis and staging of RCC due to its renal excretion. This review focuses on the clinical role and current status of FDG PET and PET/CT in RCC.

Recent findings: Studies investigating the role of FDG PET in localized RCC were largely disappointing. Several studies have demonstrated that the use of hybrid imaging PET/CT is feasible in evaluating the extra-renal disease. A current review of the literature determines PET/CT to be a valuable tool both in treatment decision-making and monitoring and in predicting the survival in recurrent and metastatic RCC. PET/CT might be a viable option in the evaluation of RCC, especially recurrent and metastatic disease. PET/CT has also shown to play a role in predicting survival and monitoring therapy response.

Keywords: Fluorodeoxyglucose (FDG); Metabolically active renal cell carcinoma; Metastases; Positron emission tomography/computed tomography (PET/CT); Restaging; Therapy monitoring.

PubMed Disclaimer

References

    1. Curr Treat Options Oncol. 2003 Oct;4(5):385-90 - PubMed
    1. J Nucl Med. 2006 Nov;47(11):1803-7 - PubMed
    1. BJU Int. 2005 Sep;96(4):540-6 - PubMed
    1. BMC Cancer. 2019 Apr 2;19(1):298 - PubMed
    1. J Nucl Med. 2017 Jun;58(6):905-910 - PubMed

MeSH terms

LinkOut - more resources